

# CURRICULUM VITAE

**Amanda L. Garner, Ph.D.**

## **Current Status:**

Business Address: University of Michigan  
College of Pharmacy  
Department of Medicinal Chemistry  
NCRC B520/3343  
1600 Huron Parkway  
Ann Arbor, MI 48109

Telephone: (734) 763-2654  
Email: [algarner@umich.edu](mailto:algarner@umich.edu)  
Lab Website: [www.garnerlaboratory.com](http://www.garnerlaboratory.com)

Current Position: Professor of Medicinal Chemistry  
Director, Interdepartmental Program in Medicinal Chemistry

Other Affiliations: Professor, Program in Chemical Biology  
Emerging Leaders Council and Core Member, University of Michigan Rogel Cancer Center  
Executive Committee Member, University of Michigan College of Pharmacy

## **Education:**

Graduate: University of Pittsburgh, Pittsburgh, PA  
Ph.D. in Chemistry, 2008  
*Research Advisor:* Professor Kazunori Koide  
*Thesis Title:* Development of Fluorescein-Based Fluorescent Chemosensors and Convergent Approaches in Solid-Phase Organic Synthesis

Undergraduate: Allegheny College, Meadville, PA  
B.S. in Chemistry, Magna cum Laude, 2003  
*Research Advisor:* Professor Leonard D. Vuocolo  
*Thesis Title:* The Synthesis of Chlorine-Substituted Diamide-Diamine Manganese Complexes for Potential Use as Nitrogen-Atom-Transfer Reagents

## **Professional Record:**

*Professor*, University of Michigan, Ann Arbor, MI, September 2024 – present  
*Associate Professor*, University of Michigan, Ann Arbor, MI, September 2020 – August 2024  
*Assistant Professor*, University of Michigan, Ann Arbor, MI, August 2013 – August 2020  
*Senior Research Associate*, The Scripps Research Institute, La Jolla, CA, July 2012 – July 2013  
*Research Associate*, The Scripps Research Institute, La Jolla, CA, Dec. 2010 – June 2012  
*NIH Postdoctoral Fellow*, The Scripps Research Institute, La Jolla, CA, Nov. 2008 – Nov. 2010

## **Honors, Awards and Fellowships:**

University of Pittsburgh Department of Chemistry Distinguished Alumni Award, 2024  
Ono Pharma Breakthrough Science Initiative Award, 2023  
Catalyst Award, Dr. Ralph and Marian Falk Medical Research Trust, 2022  
Rogel Scholar, Rogel Cancer Center, 2022

ACS Division of Medicinal Chemistry David W. Robertson Award, 2022  
MAVEN Senior Scientist, Northwell Health MAVEN Institute, 2021  
Catalyst Award, Dr. Ralph and Marian Falk Medical Research Trust, 2016  
NIH Postdoctoral Fellowship, 2008  
Pitt Innovator Award, 2008  
Strem Travel Award, 2006  
Novartis Fellowship for Women and Minorities, 2005  
NASA Space Grant Fellowship, 2004  
Safford Award for Excellence as a Graduate Student Teacher, 2004  
Chairman's Scholar Grant, Ashe Fellowship, 2003  
Society for Analytical Chemistry of Pittsburgh Chemistry Award, 2003  
Phi Beta Kappa, 2003

### **Editorial Work:**

Topic Editor, *ACS Pharmacology and Translational Science*, January 1, 2022–December 31, 2023  
Guest Editor, *ACS Pharmacology and Translational Science*, Virtual Special Issue “Nucleosides, Nucleotides and Nucleic Acids as Therapeutics,” 2021–2022  
Early Career Advisory Board Member, *Journal of Medicinal Chemistry*, 2021–2024  
Editorial Advisory Board Member, *ACS Medicinal Chemistry Letters*, 2021–2023  
Advisory Board Member, *Cell Chemical Biology*, 2020–present  
Guest Editor, *ACS Medicinal Chemistry Letters*, Special Issue “RNA: Opening New Doors in Medicinal Chemistry,” 2020–2021  
Co-Editor, Topics in Biology, *Medicinal Chemistry Reviews*, 2020–2023  
Editorial Board Member, *SLAS Discovery*, 2020–present  
Associate Editor, *RSC Advances*, Royal Society of Chemistry, 2019–2021  
Series Editor, *Topics in Medicinal Chemistry*, Springer International Publishing (Cham, Switzerland), 2018–present  
“RNA Therapeutics,” [Amanda L. Garner](#) (Ed.), *Topics in Medicinal Chemistry*, Vol. 27, 2018, Springer International Publishing (Cham, Switzerland)

### **Independent Publications:**

70. O'Rourke, R. L.; [Garner, A. L.](#)\* “Chemical Probes for Studying the Eukaryotic Translation Initiation Factor 4E (eIF4E)-Regulated Translatome in Cancer.” *ACS Pharmacol. Transl. Sci.* **2025**, *accepted*.
69. Cárdenas, E. L.‡; O'Rourke, R. L.‡; Menon, A.; Vega Hernández, G.; Meagher, J. L.; Stuckey, J. A.; [Garner, A. L.](#)\* “Second-Generation Cap Analogue Prodrugs for Targeting Aberrant Eukaryotic Translation Initiation Factor 4E (eIF4E) Activity in Cancer” *ACS Med. Chem. Lett.* **2025**, *16*, 96–100. (‡Shared Authorship)
68. Sluzala, Z. B.; Shan, Y.; Elghazi, L.; Cárdenas, E. L.; Hamati, A.; [Garner, A. L.](#); Fort, P. E. “Novel mTORC2/HSPB4 interaction: role and regulation of HSPB4 T148 phosphorylation.” *Cells* **2024**, *13*, 2000.
67. Soueid, D. M.; [Garner, A. L.](#)\* “RNA-Protein Interactions: A New Approach for Drugging RNA Biology.” *Methods and Principles in Medicinal Chemistry* **2024**, *84*, 281–320.
66. Walker, N.; Ibuki, Y.; McLinden, A. P.; Misumi, K.; Mitchell, D. C.; Kleer, G.; Lock, A. M.; Vittal, R.; Sonenberg, N.; [Garner, A. L.](#); Lama, V. N. “MNK-Driven eIF4E Phosphorylation as a Key Regulator of the Fibrogenic Transformation of Mesenchymal Cell and Chronic Lung Allograft Dysfunction.” *J. Clin. Invest.* **2024**, *134*, e168393.
65. Blanco, M.-J.; Bronson, J. J.; DiMauro, E. F.; Dzierba, C.; Eggen, M.; [Garner, A. L.](#); Georg, G.; Giarolla, J.; Goodwin, N. C.; Grenier-Davies, M. C.; Haskell-Luevano, C.; Holzgrabe, U.; Huang, R.; Lagiokos, H. R.; Leftheris, K.; Martin, Y.; Matos, M. J.; May-Dracka, T. L.; Muller, C. E.; Newman, A. H.; Parmee, E.; Petter, J. C.; Tamayo, N. A.; Wexler, R. R.; Bolognesi, M. L.; Ripka, A.; Young, W. “Empowering Voices: Inspiring Women in Medicinal Chemistry.” *ACS Med. Chem. Lett.* **2024**, *15*, 424–431.
64. Blanco, M.-J.; Bronson, J. J.; DiMauro, E. F.; Dzierba, C.; Eggen, M.; [Garner, A. L.](#); Georg, G.; Giarolla, J.; Goodwin, N. C.; Grenier-Davies, M. C.; Haskell-Luevano, C.; Holzgrabe, U.; Huang, R.; Lagiokos, H. R.; Leftheris, K.; Martin, Y.; Matos, M. J.; May-Dracka, T. L.; Muller, C. E.; Newman, A. H.; Parmee, E.; Petter,

- J. C.; Tamayo, N. A.; Wexler, R. R.; Bolognesi, M. L.; Ripka, A.; Young, W. “Empowering Voices: Inspiring Women in Medicinal Chemistry.” *J. Med. Chem.* **2024**, *67*, 4251–4258.
63. Rosenblum, S. L.; Soueid, D. M.; Giambasu, G.; Vander Roest, S.; Pasternak, A.; DiMauro, E. F.; Simov, V.\*; Garner, A. L.\* “Live Cell Screening to Identify RNA-Binding Small Molecule Inhibitors of the pre-let-7–Lin28 RNA-Protein Interaction.” *RSC Med. Chem.* **2024**, *15*, 1539–1546.
62. Soueid, D. M.; Garner, A. L.\* “Adaptation of RiPCA for the Live-Cell Detection of mRNA-Protein Interactions.” *Biochemistry* **2023**, *62*, 3323–3336.
61. Cárdenas, E. L.; O’Rourke, R. L.; Menon, A.; Meagher, J. L.; Stuckey, J. A.; Garner, A. L.\* “Design and Synthesis of Cell-Permeable Inhibitors of Eukaryotic Translation Initiation Factor 4E (eIF4E).” *J. Med. Chem.* **2023**, *66*, 10734–10745.
60. Zhuang, Y.; Yang, F.; Menon, A.; Song, J. M.; Espinoza, R.; Schultz, P.; Garner, A. L.\*; Tripathi, A.\* “An ECD and NMR/DP4+ Computational Pipeline for Structural Revision and Elucidation of Diphenazine-Based Natural Products.” *J. Natl. Prod.* **2023**, *86*, 1801–1814. (\*Co-Corresponding Authors)
- **Chosen for supplementary cover art**
59. Torrez, R. M.; Nagaraja, S.; Menon, A.; Chang, L.; Ohi, M. D.\*; Garner, A. L.\* “Comparative Biochemical Studies of Disease-Associated Human Dicer Mutations on Processing of a pre-microRNA and snoRNA.” *Biochemistry* **2023**, *62*, 1725–1734. (\*Co-Corresponding Authors)
58. Aldrich, J.; Allen, S.; Araujo, E.; Bronson, J.; Bryant-Friedrich, A.; Cyr, S. K.; DiMauro, E. F.; Dzierba, C.; Garner, A. L.; Georg, G.; Goodwin, N. C.; Haranahali, K.; Huang, R.; Leftheris, K.; May-Dracka, T. L.; Olson, M. E.; Blanco, M.-J. “Enhancing the Visibility of Women in the ACS Division of Medicinal Chemistry (ACS MEDI).” *ACS Med. Chem. Lett.* **2023**, *14*, 345–349.
57. Aldrich, J.; Allen, S.; Araujo, E.; Bronson, J.; Bryant-Friedrich, A.; Cyr, S. K.; DiMauro, E. F.; Dzierba, C.; Garner, A. L.; Georg, G.; Goodwin, N. C.; Haranahali, K.; Huang, R.; Leftheris, K.; May-Dracka, T. L.; Olson, M. E.; Blanco, M.-J. “Enhancing the Visibility of Women in the ACS Division of Medicinal Chemistry (ACS MEDI).” *J. Med. Chem.* **2023**, *66*, 3651–3655.
56. Garner, A. L. “Contemporary Progress and Opportunities in RNA-Targeted Drug Discovery.” *ACS Med. Chem. Lett.* **2023**, *14*, 251–259.
- **Included in the virtual special issue “New Enabling Drug Discovery Technologies – Recent Progress”**
  - **Included in the *ACS Med. Chem. Lett.* “Future of Medicinal Chemistry” collection: <https://pubs.acs.org/page/amclct/vi/future-medicinal-chemistry>**
55. Torrez, R. M.; Ohi, M. D.\*; Garner, A. L.\* “Structural Insights into the Advances and Mechanistic Understanding of Human Dicer.” *Biochemistry* **2023**, *62*, 1–16. (\*Co-Corresponding Authors)
54. Rosenblum, S. L.; Garner, A. L. “Optimization of RiPCA for the Live-Cell Detection of Pre-microRNA-Protein Interactions.” *ChemBioChem* **2022**, *23*, e202200508.
53. Rosenblum, S. L.; Garner, A. L. “RiPCA: An Assay for the Detection of RNA-Protein Interactions in Live Cells.” *Curr. Protoc. Chem. Biol.* **2022**, *2*, e358.
52. Garner, A. L. “Nucleosides, Nucleotides and Nucleic Acids as Therapeutics: A Virtual Special Issue.” *ACS Pharmacol. Transl. Sci.* **2021**, *4*, 1714–1715.
51. Robertson, A. W.; Sandoval, J.; Mohamed, O. G.; Zhuang, Y.; Gallagher, E. E.; Schmidt, J. J.; Caratelli, L.; Menon, A.; Schultz, P. J.; Torrez, R. M.; Hay, C. L.; Bell, B. A.; Price, P. A.; Garner, A. L.\*; Tripathi, A.\* “Discovery of Surfactins as Inhibitors of microRNA Processing Using cat-ELCCA.” *ACS Med. Chem. Lett.* **2021**, *12*, 878–886. (\*Co-Corresponding Authors)
50. Garner, A. L.; Djuric, S. W. “RNA: Opening New Doors in Medicinal Chemistry, A Special Issue.” *ACS Med. Chem. Lett.* **2021**, *12*, 851–853.
49. Rosenblum, S. L.‡; Lorenz, D. A.‡; Garner, A. L. “A Live-Cell Assay for the Detection of pre-microRNA-Protein Interactions.” *RSC Chem. Biol.* **2021**, *2*, 241–247. (‡Shared Authorship)
- **Chosen as a 2021 Editors’ Choice article**
  - **Highlighted by Promega Connections: <https://www.promegaconnections.com/rna-protein-interactions-garner/>**
  - **Featured by Promega as part of their “Targeting RNA in Drug Discovery” application site: <https://www.promega.com/applications/small-molecule-drug-discovery/targeting-rna/>**

48. Garner, A. L.; Djuric, S. W. “RNA: Opening New Doors in Medicinal Chemistry.” *ACS Med. Chem. Lett.* **2020**, *11*, 1659–1660.
47. Gallagher, E. E.; Menon, A.; Chmiel, A. F.; Deprey, K.; Kritzer, J. A.; Garner, A. L. “A Cell-Penetrant Lactam Stapled Peptide for Targeting eIF4E Protein-Protein Interactions.” *Eur. J. Med. Chem.* **2020**, *205*, 112655.
46. Mitchell, D. C.; Menon, A.; Garner, A. L. “Cyclin-Dependent Kinase 4 Inhibits the Translational Repressor 4E-BP1 to Promote Cap-Dependent Translation During Mitosis-G1 Transition.” *FEBS Lett.* **2020**, *594*, 1307–1318.
- **Chosen as the cover article**
45. Sherman, E. J.; Mitchell, D. C.; Garner, A. L. “The RNA-Binding Protein SART3 Promotes miR-34a Biogenesis and G1 Cell Cycle Arrest.” *J. Biol. Chem.* **2019**, *294*, 17188–17196.
44. Garner, A. L. “RNA-Targeted Drug Discovery: Moving Beyond Promiscuous Small Molecule Scaffolds.” *Fut. Med. Chem.* **2019**, *11*, 2487–2490.
43. Song, J. M.; Gallagher, E. E.; Menon, A.; Mishra, L. D.; Garner, A. L. “The Role of Olefin Geometry in the Activity of Hydrocarbon Stapled Peptide Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E).” *Org. Biomol. Chem.* **2019**, *17*, 6414–6419.
42. Sherman, E. J.‡; Lorenz, D. A.‡; Garner, A. L. “Click Chemistry-Mediated Complementation Assay for RNA-Protein Interactions.” *ACS Comb. Sci.* **2019**, *21*, 522–527. (‡Shared Authorship)
41. Gallagher, E. E.‡; Song, J. M.‡; Menon, A.; Mishra, L. D.; Chmiel, A. F.; Garner, A. L. “Consideration of Binding Kinetics in the Design of Stapled Peptide Mimics of the Disordered Proteins Eukaryotic Translation Initiation Factor 4E-Binding Protein 1 and Eukaryotic Translation Initiation Factor 4G.” *J. Med. Chem.* **2019**, *62*, 4967–4978. (‡Shared Authorship)
40. Garner, A. L.; Lorenz, D. A.; Gallagher, E. E. “A Click Chemistry Assay to Identify Natural Product Ligands for pre-microRNAs.” *Methods Enzymol.* **2019**, *623*, 85–99.
39. Garner, A. L.; Lorenz, D. A.‡; Sandoval, J.‡; Gallagher, E. E.; Kerk, S. A.; Kaur, T.; Menon, A. “Tetracyclines as Inhibitors of pre-microRNA Maturation: A Disconnection Between RNA Binding and Inhibition.” *ACS Med. Chem. Lett.* **2019**, *10*, 816–821. (‡Shared Authorship)
38. Mitchell, D. C.; Menon, A.; Garner, A. L. “Chemoproteomic Profiling Uncovers CDK4-Mediated Phosphorylation of the Translational Suppressor 4E-BP1.” *Cell Chem. Biol.* **2019**, *26*, 980–990.
37. Kaur, T.; Menon, A.; Garner, A. L. “Synthesis of 7-Benzylguanosine Cap Analogue Conjugates for eIF4E Targeted Degradation.” *Eur. J. Med. Chem.* **2019**, *166*, 339–350.
36. Johnson, O. T.; Kaur, T.; Garner, A. L. “A Conditionally Fluorescent Peptide Reporter of Secondary Structure Modulation.” *ChemBioChem* **2019**, *20*, 40–45.
- **Invited as part of the ChemBioTalents issue**
  - **Selected as a VIP Manuscript and highlighted in *ChemistryViews***
  - **Top downloaded paper (top 10%) from 2018–2019**
35. Garner, A. L. “cat-ELCCA: Catalyzing Drug Discovery Through Click Chemistry.” *Chem. Commun.* **2018**, *54*, 6531–6539.
- **Invited as part of the Emerging Investigators issue**
34. Lorenz, D. A.; Kaur, T.; Kerk, S. A.; Gallagher, E. E.; Sandoval, J. Garner, A. L. “Expansion of cat-ELCCA for the Discovery of Small Molecule Inhibitors of the Pre-let-7–Lin28 RNA-Protein Interaction.” *ACS Med. Chem. Lett.* **2018**, *9*, 517–521.
- **Chosen as the Feature cover article**
  - **Chosen as an ACS Editors’ Choice article**
33. Lorenz, D. A.; Vander Roest, S.; Larsen, M. J.; Garner, A. L. “Development and Implementation of an HTS-Compatible Assay for the Discovery of Selective Small Molecule Ligands for pre-microRNAs.” *SLAS Discovery* **2018**, *23*, 47–54.
- **Featured in *C&E News* “The RNA Drug Hunters” 2017, November 27 issue, pg. 16–18**
  - **Featured in *The Scientist*: <https://www.the-scientist.com/lab-tools/drug-discovery-techniques-open-the-door-to-rna-targeted-drugs-65903>**
  - **One of the top 10 most cited papers in *SLAS Discovery* from 2018–2020**
32. Song, J. M.; Menon, A.; Mitchell, D. C.; Johnson, O. T.; Garner, A. L. “High-Throughput Chemical Probing of Full-Length Protein-Protein Interactions.” *ACS Comb. Sci.* **2017**, *19*, 763–769.

- **Chosen as the cover article**
31. Lorenz, D. A.; Garner, A. L. “Approaches for the Discovery of Small Molecule Ligands Targeting microRNAs.” *Topics Med. Chem.* **2018**, *27*, 79–110.
  30. Lorenz, D. A.; Garner, A. L. “A Click Chemistry-Based microRNA Maturation Assay Optimized for High-Throughput Screening.” *Chem. Commun.* **2016**, *52*, 8267–8270.
    - **Featured in *The Scientist***: <https://www.the-scientist.com/lab-tools/drug-discovery-techniques-open-the-door-to-rna-targeted-drugs-65903>
  29. Hart, J. R.; Weinberg, M. S.; Morris, K. V.; Roberts, T. C.; Janda, K. D.; Garner, A. L.; Vogt, P. K. “MINCR is Not a MYC-Induced lncRNA.” *Proc. Natl. Acad. Sci., U. S. A.* **2016**, *113*, E496–E497.
  28. Lorenz, D. A.; Song, J. M.; Garner, A. L. “High-Throughput Platform Assay Technology for the Discovery of pre-microRNA-Selective Small Molecule Probes.” *Bioconj. Chem.* **2015**, *26*, 19–23.

### **Post Doc Publications:**

27. Hart, J. R.\*; Garner, A. L.\*; Yu, J.; Ito, Y.; Sun, M.; Ueno, L.; Rhee, J.-K.; Baksh, M. M.; Stefan, E.; Hartl, M.; Bister, K.; Vogt, P. K.; Janda, K. D. “An Inhibitor of MYC Identified in a Kröhnke Pyridine Library.” *Proc. Natl. Acad. Sci., U. S. A.* **2014**, *111*, 12556–12561. (\*Co-First Authorship)
26. Garner, A. L.; Fullagar, J. L.; Day, J. A.; Cohen, S. M.; Janda, K. D. “Development of a High-Throughput Screen and Its Use in the Discovery of *Streptococcus pneumoniae* Immunoglobulin A1 Protease (IgA1P) Inhibitors.” *J. Am. Chem. Soc.* **2013**, *135*, 10014–10017.
25. Kravchenko, V. V.; Garner, A. L.; Mathison, J. C.; Seit-Nebi, A.; Yu, J.; Gileva, I. P.; Ulevitch, R. J.; Janda, K. D. “Facilitating Cytokine-Mediated Cancer Cell Death by Proteobacterial *N*-Acylhomoserine Lactones.” *ACS Chem. Biol.* **2013**, *8*, 1117–1120.
24. Fullagar, J. L.\*; Garner, A. L.\*; Struss, A. K.; Day, J. A.; Martin, D. P.; Cai, X.; Janda, K. D.; Cohen, S. M. “Antagonism of a Zinc Metalloprotease Using a Unique Metal-Chelating Scaffold: Tropolones as Inhibitors of *P. aeruginosa* Elastase.” *Chem. Commun.* **2013**, *49*, 3197–3199. (\*Co-First Authorship)
23. Garner, A. L.; Yu, J.; Struss, A. K.; Kaufmann, G. F.; Kravchenko, V. V.; Janda, K. D. “Immunomodulation and the Quorum Sensing Molecule 3-Oxo-C<sub>12</sub>-Homoserine Lactone: The Importance of Chemical Scaffolding for Probe Development.” *Chem. Commun.* **2013**, *49*, 1515–1517.
22. Garner, A. L.; Struss, A. K.; Fullagar, J. L.; Agrawal, A.; Moreno, A. Y.; Cohen, S. M.; Janda, K. D. “3-Hydroxy-1-alkyl-2-methylpyridine-4(1*H*)-thiones: Inhibition of the *Pseudomonas aeruginosa* Virulence Factor LasB.” *ACS Med. Chem. Lett.* **2012**, *3*, 668–672.
21. Li, Z.; Garner, A. L.; Gloeckner, C.; Janda, K. D.; Carlow, C. K. S. “Targeting the *Wolbachia* Cell Division Protein FtsZ as a New Approach for Antifilarial Therapy.” *PLoS Negl. Trop. Dis.* **2011**, *5*, e1411.
20. Garner, A. L.; Park, J.; Zakhari, J. S.; Lowery, C. A.; Struss, A. K.; Sawada, D.; Kaufmann, G. F.; Janda, K. D. “A Multivalent Probe for AI-2 Quorum Sensing Receptors.” *J. Am. Chem. Soc.* **2011**, *133*, 15934–15937.
  - **Featured in *ChemBioChem* 2012, 13, 508–510**
19. Garner, A. L.; Janda, K. D. “A Small Molecule Antagonist of Ghrelin *O*-Acyltransferase (GOAT).” *Chem. Commun.* **2011**, *47*, 7512–7514.
18. Garner, A. L.; Gloeckner, C.; Tricoche, N.; Zakhari, J. S.; Samje, M.; Cho-Ngwa, F.; Lustigman, S.; Janda, K. D. “Design, Synthesis and Biological Activities of Closantel Analogues: Structural Promiscuity and Its Impact on *Onchocerca volvulus*.” *J. Med. Chem.* **2011**, *54*, 3963–3972.
17. Uckun, F. M.; Qazi, S.; Ozer, Z.; Garner, A. L.; Pitt, J.; Ma, H.; Janda, K. D. “Inducing Apoptosis in Chemotherapy-Resistant B-Lineage Acute Lymphoblastic Leukemia (ALL) Cells by Targeting GRP78/HSPA5, A Master Regulator of the Anti-Apoptotic Unfolded Protein Response (UPR) Signaling Network.” *Br. J. Haematol.* **2011**, *153*, 741–752.
16. Kirchdoerfer, R. N.; Garner, A. L.; Flack, C. E.; Mee, J. M.; Horswill, A. R.; Janda, K. D.; Kaufmann, G. F.; Wilson, I. A. “Structural Basis for Ligand Recognition and Discrimination of a Quorum-quenching Antibody.” *J. Biol. Chem.* **2011**, *286*, 17351–17358.

15. Garner, A. L.; Yu, J.; Struss, A. K.; Lowery, C. A.; Zhu, J.; Kim, S. K.; Park, J.; Mayorov, A. V.; Kaufmann, G. F.; Kravchenko, V. V.; Janda, K. D. "Synthesis of 'Clickable' Bacterial Autoinducing Probes: Unanticipated Effects on Mammalian Cell Activation." *Bioorg. Med. Chem. Lett.* **2011**, *21*, 2702–2705.
14. Garner, A. L.; Janda, K. D. "Shedding Light on the Ghrelin/GOAT Metabolism Saga." *ChemBioChem* **2011**, *12*, 523–525.
13. Garner, A. L.; Janda, K. D. "Protein-Protein Interactions and Cancer: Targeting the Central Dogma." *Curr. Topics Med. Chem.* **2011**, *11*, 258–280.
12. Garner, A. L.; Janda, K. D. "cat-ELCCA: A Robust Method to Monitor the Fatty Acid Acyltransferase Activity of Ghrelin O-Acyltransferase (GOAT)." *Angew. Chem. Int. Ed.* **2010**, *49*, 9630–9634.
  - **Featured in C&E News 2010, September 27 issue, pg. 15**
11. Gloeckner, C.; Garner, A. L.; Mersha, F.; Oksov, Y.; Tricoche, N.; Eubanks, L. M.; Lustigman, S.; Kaufmann, G. F.; Janda, K. D. "Repositioning of an Existing Drug for the Neglected Tropical Disease Onchocerciasis." *Proc. Natl. Acad. Sci., U. S. A.* **2010**, *107*, 3424–3429.
  - **Featured in Science Now: <http://news.sciencemag.org/sciencenow/2010/02/09-01.html>**
  - **Featured in C&E News 2010, February 22 issue, pg. 35**

### Graduate Publications:

10. Koide, K.; Osman, S.; Garner, A. L.; Song, F.; Dixon, T.; Greenberger, J. S.; Epperly, M. W. "The Use of 3,5,4'-Tri-O-acetylresveratrol as a Potential Pro-drug for Resveratrol Protects Mice from  $\gamma$ -Irradiation-Induced Death." *ACS Med. Chem. Lett.* **2011**, *2*, 270–274.
  - **Featured in Newsweek: <http://www.newsweek.com/2011/05/15/newsbeast-health.html>**
9. Garner, A. L.; St. Croix, C. M.; Pitt, B. R.; Leikauf, G. D.; Ando, S.; Koide, K. "Specific Fluorogenic Probes for Ozone in Biological and Atmospheric Samples." *Nat. Chem.* **2009**, *1*, 316–321.
  - **Featured by the RSC: <http://www.rsc.org/chemistryworld/News/2009/May/31050901.asp>**
  - **Featured in Nature Methods: <http://www.nature.com/nmeth/journal/v6/n8/full/nmeth0809-557.html>**
8. Garner, A. L.; Song, F.; Koide, K. "Enhancement of a Catalysis-Based Fluorometric Detection Method for Palladium through Rational Fine-Tuning of the Palladium Species." *J. Am. Chem. Soc.* **2009**, *131*, 5163–5171.
7. Uchida, T.; Mills, K. L.; Kuo, C-H.; Roh, W.; Tung, Y-C.; Garner, A. L.; Koide, K.; Thouless, M. D.; Takayama, S. "External Compression-Induced Fracture Patterning on the Surface of Poly(dimethylsiloxane) Cubes and Microspheres." *Langmuir* **2009**, *25*, 3102–3107.
6. Garner, A. L.; Koide, K. "Studies of Fluorogenic Probe for Palladium and Platinum Leading to a Palladium-Specific Detection Method." *Chem. Commun.* **2009**, 86–88.
5. Garner, A. L.; Koide, K. "Fluorescent Method for Platinum Detection in Buffers and Serum for Occupational Hazard and Cancer Medicine." *Chem. Commun.* **2009**, 83–85.
4. Garner, A. L.; Koide, K. "Oxidation State-Specific Fluorescent Method for Palladium(II) and Platinum(IV) Based on the Catalyzed Aromatic Claisen Rearrangement." *J. Am. Chem. Soc.* **2008**, *130*, 16472–16473.
3. Koide, K.; Song, F.; de Groh, E. D.; Garner, A. L.; Mitchell, V. D.; Davidson, L. A.; Hukriede, N. A. "Scalable and Concise Synthesis of Dichlorofluorescein Derivatives Displaying Tissue Permeation in Live Zebrafish Embryos." *ChemBioChem* **2008**, *9*, 214–218.
2. Garner, A. L.; Koide, K. "Solid-Phase Olefin Cross-Metathesis Promoted by a Linker." *Org. Lett.* **2007**, *9*, 5235–5238.
  - **Featured in C&E News 2007, November 26 issue, pg. 8**
  - **Highlighted in Synfacts, 2008, pg. 0211**
1. Song, F.; Garner, A. L.; Koide, K. "A Highly Sensitive Fluorescent Sensor for Palladium Based on the Allylic Oxidative Insertion Mechanism." *J. Am. Chem. Soc.* **2007**, *129*, 12354–12355.
  - **Featured in C&E News 2007, October 1 issue, pg. 30**

## Patents:

- Koide, K.; Garner, A. L. “Fluorescent Sensor for Ozone.” U.S. Pat. Appl. Publ. (2010), US 20100255525 A1 20101007.
- Koide, K.; Garner, A. L. “Methods of Determining the Oxidation State of Platinum and Palladium Using Fluorogenic Probes.” Provisional patent filed on July 14, 2008.
- Koide, K.; Garner, A. L. “Preparation of Hydroxymethyl Fluorescein Derivatives for Use as Biological Markers and Dyes.” WO 2008094502 A1 20080807.
- Koide, K.; Garner, A. L.; Song, F. “Detection of Platinum Group Metals with Fluorophores via Allylic Oxidative Insertion.” WO 2008094496 A1 20080807.
  - This chemosensor was licensed to and commercialized by Arbor Assays, LLC ([www.arborsassays.com/products/inserts/K007-F1\\_product.pdf](http://www.arborsassays.com/products/inserts/K007-F1_product.pdf)).

## Research Support:

### *Active:*

R35 GM153185 (PI: Garner) 09/01/2024 – 07/31/2029  
NIH/NIGMS \$1,760,000 (direct costs)

### **Chemical Biology Approaches for Investigating RNA-Protein Interactions**

The overall goal of this project is to develop innovative technologies and chemical probes to advance the field of targeting cellular RNA-protein interactions.

2-22816-99-01-G1/HT9425-23-LCRP-IDA (PI: Rix) 07/01/2024 – 06/30/2026  
Moffitt Cancer Center/DoD \$53,827 (direct costs)

### **Dual Up- and Downstream Targeting of POU2F3 in Small Cell Lung Cancer**

The overall goal of this project is to use PhAXA to identify novel kinases that can phosphorylate POU2F3 in small cell lung cancer cells.

No number (PI: Garner) 01/01/2023 – 12/31/2024  
Michigan Center for Therapeutic Innovation \$150,000 (direct costs)

### **eIF4E-Targeted Inhibitors for the Treatment of Drug Resistant, Metastatic Melanoma**

The overall goal of this project is to develop eIF4E-targeted small molecule inhibitors as novel cancer therapeutics.

No number (PI: Garner) 07/01/2022 – 06/30/2025  
Rogel Cancer Center \$150,000 (direct costs)

### **Rogel Scholar Award**

This award provides discretionary funding to initiate and continue cancer-related drug discovery projects.

### *Completed:*

No number (PI: Garner) 11/30/2022 – 11/29/2024  
Dr. Ralph and Marian Falk Medical Research Trust \$272,727 (direct costs)

### **Decoding the Druggable Transcriptome**

The overall goal of this project is to develop chemical probing technology for RNA-binding small molecules applied towards identifying RNA-modulating inhibitors of AR-V7 splicing in prostate cancer.

R01 GM132342 S1 (PI: Garner) 09/01/2022 – 08/31/2024  
NIH/NIGMS \$112,777 (direct costs)

### **Delineating the Biology of Translational Repressor 4E-BP1: Diversity Supplement**

The overall goal of this project is to support the graduate research of Gabriela Vega-Hernández in developing a new chemical biology approach for targeting eIF4E and cap-dependent translation.

R01 GM135252 S1 (PI: Garner) 09/01/2021 – 08/31/2024  
NIH/NIGMS \$115,520 (direct costs)

## **Chemical Biology Approach for Validating and Manipulating Cellular RNA-Protein Interactions: Diversity Supplement**

The overall goal of this project is to support the graduate research of José Reyes in developing a new chemical biology approach for RNA-targeted drug discovery.

R01 GM132342 (PI: Garner) 09/01/2020 – 08/31/2024  
NIH/NIGMS \$800,000 (direct costs)

### **Delineating the Biology of Translational Repressor 4E-BP1**

The overall goal of this project is to investigate the biology of 4E-BP1, the gate-keeper of cap-dependent translation using chemical biology techniques. Through these studies, we will not only further enhance our knowledge of 4E-BP1-mediated translational regulation, but also illuminate new druggable targets for treatment of the many diseases associated with aberrant cap-dependent translation.

R01 GM135252 (PI: Garner) 09/20/2019 – 08/31/2024  
NIH/NIGMS \$790,000 (direct costs)

### **Chemical Biology Approach for Validating and Manipulating Cellular RNA-Protein Interactions**

The overall goal of this project is to further develop an organelle-specific live cell detection assay for RNA-protein interactions developed in our laboratory, RNA interaction with Protein-mediated Complementation Assay, or RiPCA.

MDD22203S (PI: Garner) 02/01/2022 – 07/31/2024  
Michigan Drug Discovery \$72,810 (direct costs)

### **Bioactivity-Guided Natural Products Discovery to Identify Inhibitors of Oncogenic pre-miR-21**

The overall goal of this project is to use bioactivity-guided natural products discovery to identify new classes of inhibitors of Dicer-mediated pre-microRNA-21 maturation.

No number (PI: Garner) 01/01/2024 – 05/31/2024  
Prism Biolabs \$17,169 (direct costs)

### **PRISM Biolabs: CETSA**

The overall goal of this project was to use our laboratory's cellular thermal shift assay (CETSA) to test Prism Biolabs compounds.

No number (PI: Garner) 02/01/2021 – 01/03/2023  
Merck \$50,000

### **Identification and Validation of Novel Small Molecule Inhibitors of the pre-let-7–Lin28 RNA-Protein Interaction to Restore let-7-Mediated Tumor Suppression**

The overall goal of this project is to discover and characterize small molecule inhibitors of the pre-let-7–Lin28 RNA-Protein Interaction using Garner laboratory assays coupled with virtual screening capabilities.

No number (PI: Garner) 01/11/2021 – 07/10/2022  
UM College of Pharmacy Upjohn Award \$50,000

### **Development of a Chemotranscriptomic Profiling Platform for RNA-Targeted Drug Discovery**

The overall goal of this project is to develop an integrated chemotranscriptomic pipeline to facilitate the target agnostic discovery of RNA-binding small molecules with disease-relevant cellular phenotypes allowing us to finally decode the druggable transcriptome.

No number (PI: Garner) 04/01/2021 – 03/31/2022  
Prism Biolabs \$64,419 (direct costs)

### **PRISM Biolabs: eIF4E Testing**

The overall goal of this project was to use our laboratory's cat-ELCCA for eIF4E protein-protein interactions to test Prism Biolabs compounds.

R01 CA202018 (PI: Garner) 07/01/2016 – 06/30/2022  
NIH/NCI \$1,143,750



#### **4E-BP Mimetics as Chemical Probes for Studying Translational Control in Cancer**

The overall goal of this project is to further develop 4E-BP stapled peptides as chemical probes targeting the eIF4E–4E-BP PPI and fully decipher their mechanism-of-action through proteomic and cellular analyses.

MDD20204-RCC (PI: Garner) 01/01/2020 – 03/31/2020  
Michigan Drug Discovery \$75,000

#### **Bioactivity-Guided Natural Products Discovery to Identify Inhibitors of eIF4E**

The overall goal of this project is to use bioactivity-guided natural products discovery to identify new classes of inhibitors of the translation initiation factor eIF4E.

R01 GM118329 (PI: Garner) 04/01/2016 – 03/31/2019  
NIH/NIGMS \$600,000

#### **Discovery of Selective Small Molecule Probes for pre-microRNAs**

The overall goal of this project is to use high-throughput assay technology developed in our laboratory to discover modulators for pre-microRNAs implicated in human disease. To do so, we will optimize our existing assay to enable two-dimensional screening of diverse collections of small molecules and natural product libraries against libraries of pre-microRNAs. Application of this technology will enable the discovery of new chemical space for targeting RNA, illuminate its druggability and provide the basis for the development of RNA-targeted small molecule therapeutics.

No number (PI: Garner) 11/30/2016 – 08/29/2018  
Dr. Ralph and Marian Falk Medical Research Trust \$300,000

#### **Leveraging the microRNA Interactome for Cancer Drug Discovery**

The overall goals of this project are to develop a high-throughput screening assay of the let-7–Lin28 miR–miR-BP interaction for small molecule inhibitor discovery, and to develop a strategy for the discovery of miR-BPs using chemically-modified pre-miR probes.

No number (PI: Garner) 01/01/2017 – 06/30/2018  
University of Michigan CDNM \$47,739

#### **Targeting the eIF4E–4E-BP1 Protein-Protein Interaction for Cancer Drug Discovery**

The overall goal of this project is to use high-throughput assay technology developed in our laboratory to discover small molecule modulators of the eIF4E–4E-BP1 PPI. The anti-proliferative activity of discovered molecules will then be examined in cellular cancer models with mTOR hyperactivation.

No number (PI: Garner) 06/01/2017 – 05/31/2018  
University of Michigan Comprehensive Cancer Center \$75,000

#### **Identifying New Druggable Targets in Colorectal Cancer Using Chemoproteomics**

The overall goal of this project is to use a chemoproteomic ATP crosslinker to identify novel kinases responsible for mTOR inhibitor drug resistance in colorectal cancer.

No number (PI: Garner) 07/01/2015 – 06/30/2016  
American Brain Tumor Association \$50,000

#### **Targeting the eIF4E–4E-BP1 Protein-Protein Interaction for the Treatment of Malignant Brain Tumors**

The overall goal of this project is to take a two-prong approach for targeting the eIF4E–4E-BP1 PPI for glioblastoma drug discovery by identifying peptide- and small molecule-based modulators of this PPI and characterizing their cellular anti-cancer activity.

No number (PI: Garner) 05/01/2015 – 04/30/2016  
University of Michigan CDNM \$50,000

#### **High-Throughput Platform Assay Technology for the Discovery of pre-microRNA-21-Selective Inhibitors**

The overall goal of this project is to use high-throughput assay technology developed in our laboratory to discover small molecule modulators of pre-microRNA-21 maturation. These compounds will then be used to investigate the impact of miRNA-21 inhibition in cellular models of glioblastoma.

F32 DK083179 (PI: Garner; Mentor: Janda) 12/01/2008 – 11/30/2010  
NIH/NIDDK \$92,056

### **Catalytic Antibody-Based Vaccine for Weight Loss**

The overall goals of this project were a two-prong approach for the development of therapies for the treatment of weight gain: (1) to develop catalytic antibodies that specifically act on ghrelin and (2) to design inhibitors of the enzyme responsible for ghrelin's unique post-translational modification, ghrelin *O*-acyltransferase (GOAT).

#### **Invited Presentations (External):**

- “Enabling Technologies for Revealing the Druggability of RNA-Protein Interactions.” Nature RNA at the Bench and Bedside IV, La Jolla, CA, 2024.
- “Enabling Technologies for Targeting RNA-Protein Interactions.” Promega: Illuminating New Frontiers – Cracking the Undruggable Code, 2024 (virtual).
- “Enabling Technologies for Targeting RNA-Protein Interactions.” 268<sup>th</sup> ACS National Meeting, Denver, CO, 2024.
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” Ono Pharma Foundation Symposium, Boston, MA, 2024.
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” National Taiwan University School of Pharmacy Research Day and International Conference, Taipei, Taiwan, 2024.
- “Opportunities for Targeting RNA-Protein Interactions for Cancer Drug Discovery.” AACR Annual Meeting 2024, San Diego, CA, 2024.
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” Drug Discovery Chemistry 2024, RNA-Modulating Small Molecule Drugs Conference, San Diego, CA, 2024.
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” University of California, San Diego, Department of Pharmacology, La Jolla, CA, 2024.
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” International Chemical Biology Society (ICBS) 2023 Meeting, Ann Arbor, MI, 2023.
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” University of Minnesota, Department of Medicinal Chemistry, Minneapolis, MN, 2023.
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” Biogen, 2023 (virtual).
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” Boston College, Department of Chemistry, Boston, MA, 2023.
- “Enabling Technologies for Revealing the Druggability of RNA-Protein Interactions.” Anima Biotech, 2023 (virtual).
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” Nucleosides, Nucleotides and Oligonucleotides Gordon Research Conference, Newport, RI, 2023.
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” Scripps Research, Department of Chemistry, 2023.
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” Stanford University, Department of Chemistry, 2023.
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” University of California, Davis, Department of Biochemistry and Molecular Medicine, 2023.
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” University of Kansas, Department of Medicinal Chemistry, 2023.
- “Targeting eIF4E in Cancer.” 265<sup>th</sup> ACS National Meeting, Indianapolis, IN, 2023.
- “Enabling Technologies for Revealing the Druggability of RNA-Protein Interactions.” Keystone Symposia on Protein-RNA Interactions and Biomolecular Condensates, Vancouver, Canada, 2023.
- “Enabling Technologies for Targeting RNA-Protein Interactions.” 5<sup>th</sup> RNA-Targeted Drug Development Summit, 2022.
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” Maze Therapeutics, 2022 (virtual).
- “Enabling Technologies for Targeting RNA-Protein Interactions.” University of Florida, Department of Chemistry, 2022.

- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” EFMC International Symposium on Medicinal Chemistry, Nice, France, 2022.
- “Expanding Opportunities for Targeting RNA-Binding Proteins.” David W. Robertson Award Lecture, 264<sup>th</sup> ACS National Meeting, Chicago, IL, 2022.
- “Enabling Technologies for Targeting RNA-Protein Interactions.” Gordon Research Conference on Natural Products and Bioactive Compounds, Andover, NH, 2022.
- “Enabling Technologies for Targeting RNA-Protein Interactions.” Annual Symposium of the Chemical Genomics Centre of the Max Planck Society, Keynote Speaker, Dortmund, Germany, 2022.
- “Enabling Technologies for Targeting RNA-Protein Interactions.” National Taiwan University School of Pharmacy Research Day and International Conference, 2022 (virtual).
- “Live-Cell Assay Technology for Studying and Screening RNA-Protein Interactions.” Drug Discovery Chemistry 2022, RNA-Targeting Small Molecule Drugs Conference, San Diego, CA, 2022.
- “Enabling Technologies for Targeting RNA-Protein Interactions.” Ribometrix, 2022 (virtual).
- “Bioorthogonal Approaches for Understanding and Manipulating RNA Biology.” Pacificchem 2021 Congress, 2021 (virtual).
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” Genentech, Discovery Chemistry, 2021 (virtual).
- “Enabling Technologies for Targeting RNA-Protein Interactions.” 4<sup>th</sup> RNA-Targeted Drug Development Summit, 2021 (virtual).
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” University of Nebraska, Eppley Institute for Cancer Research, 2021 (virtual).
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” Advances in Drug Discovery and Development, Technology Networks Virtual Symposium, 2021.
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” Rowan University, Department of Chemistry, 2021 (virtual).
- “Enabling Technologies for Targeting RNA-Protein Interactions.” University of Puerto Rico, RISE Program, 2021 (virtual).
- “Enabling Technologies for Targeting RNA-Protein Interactions.” Discovery on Target, 2021 (virtual).
- “Enabling Technologies for Targeting RNA-Protein Interactions.” 262<sup>nd</sup> ACS National Meeting, Atlanta, GA, 2021 (virtual).
- “Understanding the Processes Behind Drug Discovery.” Xtelligent Healthcare Media Webcast, 2021.
- “Enabling Technologies for Targeting RNA-Protein Interactions.” Drug Discovery Chemistry 2021, RNA-Targeting Small Molecule Drugs Conference, 2021 (virtual).
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” University of Pittsburgh, College of Pharmacy, 2021 (virtual).
- “Chemical Probing of Coding and Non-Coding RNA Biology.” Keck Science Department of Claremont McKenna, Pitzer and Scripps Colleges, 2021 (virtual).
- “Exploration and Discovery of mRNA Regulation Targets.” Targeting RNA Congress, 2021 (virtual).
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” Syracuse University, Department of Chemistry, 2021 (virtual).
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” University of Arkansas, College of Pharmacy, 2021 (virtual).
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” Baylor College of Medicine, Department of Pharmacology and Chemical Biology, 2021 (virtual).
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” ACS Webinar in Drug Discovery, 2020.
- “Chemical Probing of Coding and Non-Coding RNA Biology.” National Cancer Institute, Frederick, MD, 2020.
- “Chemical Probing of Coding and Non-Coding RNA Biology.” National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020.
- “Chemical Probing of Coding and Non-Coding RNA Biology.” Wayne State University, Detroit, MI, 2020.

- “Chemical Probing of Coding and Non-Coding RNA Biology.” Baekeland Award Symposium, Madison, NJ, 2019.
- “Chemical Probing of Translational Control and microRNA Biology.” Western Michigan University, Department of Chemistry, Kalamazoo, MI, 2019.
- “Strategies for Targeting Aberrant microRNA Activity in Cancer.” 258<sup>th</sup> ACS National Meeting, San Diego, CA, 2019.
- “Identification of Kinase-Targeted Drug Combinations Using Chemoproteomics.” Cambridge Healthtech Institute’s 6<sup>th</sup> Annual Chemical Biology and Target Validation Conference, Boston, MA, 2019.
- “Chemical Probing of Coding and Non-Coding RNA Biology.” Gordon Research Conference (Bioorganic Chemistry), Andover, NH, 2019.
- “Chemical Probing of Translational Control and microRNA Biology.” Emory University School of Medicine, Department of Pharmacology and Chemical Biology, Atlanta, GA, 2019.
- “Chemical Probing of Translational Control and microRNA Biology.” Student-invited Speaker, Weill Cornell Medicine, Department of Pharmacology, New York, NY, 2019.
- “Chemical Probing of Translational Control and microRNA Biology.” University of Massachusetts Medical School, Department of Biochemistry and Molecular Pharmacology, Worcester, MA, 2019.
- “A Chemist Like Me.” Spelman College, Department of Chemistry, Atlanta, GA, 2019.
- “Chemical Probing of Translational Control and microRNA Biology.” University of Minnesota, Department of Medicinal Chemistry, Chemical Biology Colloquium, Minneapolis, MN, 2019.
- “Chemical Probing of Translational Control and microRNA Biology.” University of Pittsburgh, Department of Chemistry, Pittsburgh, PA, 2019.
- “Deciphering Mechanisms by which to Selectively Target Specific microRNAs for Drug Discovery.” 2<sup>nd</sup> Annual Chemical Biology in the Hub Symposium, Cambridge, MA, 2018.
- “Chemical Probing of Translational Control and microRNA Biology.” University of Notre Dame, Department of Chemistry, South Bend, IN, 2018.
- “Chemical Probing of Translational Control and microRNA Biology.” University of Illinois at Chicago, Department of Medicinal Chemistry and Pharmacognosy, Chicago, IL, 2018.
- “Deciphering Mechanisms by which to Selectively Target Specific microRNAs for Drug Discovery.” Genomics Institute of the Novartis Research Foundation, San Diego, CA, 2018.
- “High-Throughput Platform Assay Technology for the Discovery of pre-microRNA-Selective Small Molecule Probes.” International Roundtable on Nucleosides, Nucleotides and Nucleic Acids, La Jolla, CA, 2018.
- “Deciphering Mechanisms by which to Selectively Target Specific microRNAs for Drug Discovery.” Gordon Research Conference (Medicinal Chemistry), New London, NH, 2018.
- “Deciphering Mechanisms by which to Selectively Target Specific microRNAs for Drug Discovery.” Third Rock Ventures, Boston, MA, 2018.
- “Chemical Probing of Translational Control and microRNA Biology.” Wayne State University, Department of Chemistry, Detroit, MI, 2018.
- “Chemical Probing of Translational Control and microRNA Biology.” Abbvie, Chicago, IL, 2018.
- “Chemical Probing of Translational Control and microRNA Biology.” Rutgers University, Department of Microbiology, Biochemistry and Molecular Genetics, Newark, NJ, 2018.
- “High-Throughput Platform Assay Technology for the Discovery of pre-microRNA-Selective Small Molecule Probes.” 255<sup>th</sup> ACS National Meeting, New Orleans, LA, 2018.
- “Chemical Probing of Translational Control and microRNA Biology.” University of Washington, Department of Chemistry, Seattle, WA, 2018.
- “Chemical Probing of Translational Control and microRNA Biology.” Ohio State University, Center for RNA Biology, Columbus, OH, 2017.
- “Chemical Probing of Translational Control in Cancer.” University of Toledo, College of Pharmacy and Pharmaceutical Sciences, Department of Medicinal and Biological Chemistry, Toledo, OH, 2017.
- “Chemical Probing of Translational Control in Cancer.” Purdue University, Department of Chemistry, West Lafayette, IN, 2017.

- “High-Throughput Platform Assay Technology for the Discovery of pre-microRNA-Selective Small Molecule Probes.” Arrakis Therapeutics, Waltham, MA, 2017.
- “High-Throughput Platform Assay Technology for the Discovery of pre-microRNA-Selective Small Molecule Probes.” New York Academy of Sciences, New York, NY, 2017.
- “Lessons Learned from a Past Attendee: My Life as an Assistant Professor August 1, 2013–Present.” ASBMB Mentoring and Grant Writing Workshop, Washington, DC, 2017.
- “Lessons Learned from Employing High-Throughput Screening to Identify Small Molecule microRNA Ligands.” Cambridge Healthtech Institute’s 12<sup>th</sup> Annual Drug Discovery Chemistry Conference, Short Course, San Diego, CA, 2017.
- “Chemical Approaches for Targeting Translational Control.” Department of Chemistry, Oakland University, 2017.
- “Chemical Approaches for Targeting Translational Control.” Department of Chemistry and Biochemistry, Andrews University, 2017.
- “High-Throughput Platform Assay Technology for the Discovery of pre-microRNA-Selective Small Molecule Probes.” 251<sup>st</sup> ACS National Meeting, San Diego, CA, 2016.
- “Targeting Translational Control in Cancer: From End to End.” Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 2015.
- “High-Throughput Platform Assay Technology for the Discovery of pre-microRNA-Selective Small Molecule Probes.” 249<sup>th</sup> ACS National Meeting, Denver, CO, 2015.
- “Chemical Approaches for Studying the Biology of Translational Repressor 4E-BP1.” ASBMB Mentoring Workshop for Early Career Scientists, Washington, DC, 2014.

#### **Invited Presentations (University of Michigan):**

- “Enabling Technologies for Targeting RNA-Protein Interactions.” Cellular Biotechnology Training Program Symposium 2022.
- “Enabling Technologies for Revealing Druggable Paths in RNA Biology.” Rogel Cancer Center, DT/TACR Monthly Meeting, 2021.
- “A Multi-Faceted Approach for Studying RNA-Binding Proteins.” Rogel Cancer Center Grand Rounds, 2020.
- “Chemical Biology Approaches for Studying the Translational Regulator 4E-BP1.” 6<sup>th</sup> Annual Protein Folding Diseases Initiative Symposium, 2019.
- “Approaches for Studying Aberrant Translation Regulation in Cancer.” Rogel Cancer Center Retreat, 2019.
- “Identification of Kinase-Targeted Drug Combinations Using Chemoproteomics.” Cayman Chemical Sponsored Symposium on Reinventing Drug Discovery through Chemical Biology, 2019.
- “Chemical Probing of Translational Control and microRNA Biology.” Department of Medicinal Chemistry, 2018.
- “RNA: The Last Frontier in Drug Discovery.” University of Michigan Bicentennial Feast of Ideas, 2017.
- “Chemical Probing of Translational Control in Cancer.” Center for the Discovery of New Medicines, 2017.
- “Progress Toward the Discovery of microRNA-21-Selective Small Molecules.” Center for RNA Biomedicine, RNA Innovation Seminar, 2016.
- “Chemical Approaches for Targeting Translational Control.” Keynote Speaker, Inaugural ACS Medicinal Chemistry Symposium, 2016.
- “Chemical Approaches for Targeting Translational Control.” Keynote Speaker, Interdisciplinary REU Program Closing Symposium, 2016.
- “High-Throughput Platform Assay Technology for the Discovery of pre-microRNA-Selective Small Molecule Probes.” Inaugural Center for RNA Biomedicine Symposium, 2016.
- “RNA: The Last Frontier in Drug Discovery (how can we solve this problem?).” Ignite Talk, College of Pharmacy Faculty Meeting, 2016.
- “Targeting Translational Control in Cancer.” Student-Invited Chalk Talk, Chemistry Biology Interface Training Program, 2015.
- “Targeting Translational Control in Cancer: From End to End.” Translational Oncology Program, 2014.

### **Invited Presentations (Graduate and Post Doc):**

- “Expanding the Scope of Organic Chemistry: Applications in Assay Design and Chemical Probe Discovery.” University of Michigan, College of Pharmacy, Ann Arbor, MI, 2013.
- “Expanding the Scope of Organic Chemistry: Applications in Assay Design and Chemical Probe Discovery.” University of California, San Diego, Department of Chemistry, La Jolla, CA, 2012.
- “Expanding the Scope of Organic Chemistry: Applications in Assay Design and Chemical Probe Discovery.” UNC Eshelman School of Pharmacy, Division of Chemical Biology and Medicinal Chemistry, Chapel Hill, NC, 2012.
- “Expanding the Scope of Organic Chemistry: Applications in Assay Design and Chemical Probe Discovery.” Indiana University School of Medicine, Department of Biochemistry and Molecular Biology, Indianapolis, IN, 2012.
- “Diagnostic and Therapeutic Approaches for the Elimination of Onchocerciasis.” Plenary Lecture, The American Association of Veterinary Parasitologists (AAVP) 57<sup>th</sup> Annual Meeting, San Diego, CA, 2012.
- “Chemical Design Principles for the Discovery of Protein-Protein Interaction Inhibitors.” Keynote Presentation, Cambridge Healthtech Institute’s 5<sup>th</sup> Annual Protein-Protein Interactions as Drug Targets Symposium, San Diego, CA, 2012.
- “Expanding the Scope of Organic Chemistry: Applications in Assay Design and Chemical Probe Discovery.” University of Kansas, Department of Chemistry, Lawrence, KS, 2012.
- “Expanding the Scope of Organic Chemistry: Applications in Assay Design and Chemical Probe Discovery.” University of Pittsburgh, School of Pharmacy, Pittsburgh, PA, 2011.
- “Development of a Convergent Approach in Solid-Phase Organic Synthesis.” Novartis Fellowship Symposium, Boston, MA, 2006.
- “Development of a Convergent Approach in Solid-Phase Organic Synthesis: Resin-to-Resin Olefin Cross-Metathesis Between Two Spatially Separated Substrates.” 232<sup>nd</sup> ACS National Meeting, San Francisco, CA, 2006.

### **Poster Presentations:**

- “Chemoproteomic Profiling Uncovers CDK4-Mediated Control of Cap-Dependent Translation.” Gordon Research Conference (Bioorganic Chemistry), Andover, NH, 2018.
- “High-Throughput Platform Assay Technology for the Discovery of pre-microRNA-Selective Small Molecule Probes.” Gordon Research Conference (High-Throughput Chemistry and Chemical Biology), Andover, NH, 2017.
- “4E-BP1 Mimetics as Chemical Probes for Studying Translational Control in Cancer.” Gordon Research Conference (Bioorganic Chemistry), Andover, NH, 2017.
- “Probing the Structure-Function of Translational Suppressor 4E-BP1.” Cold Spring Harbor Translational Control Meeting, Cold Spring Harbor, NY, 2016.
- “Targeting Translational Control in Cancer.” Gordon Research Conference (High-Throughput Chemistry and Chemical Biology), New London, NH, 2015.
- “cat-ELCCA: A Robust Method to Monitor the Fatty Acid Acyltransferase Activity of Ghrelin O-Acyltransferase (GOAT).” Gordon Research Conference (High-Throughput Chemistry and Chemical Biology), New London, NH, 2011.
- “The Synthesis of Chlorine-Substituted Diamide-Diamine Manganese Complexes for Potential Use as Nitrogen-Atom Transfer Reagents.” 225<sup>th</sup> ACS National Meeting, New Orleans, LA, 2003.

### **Teaching Experience:**

#### *University of Michigan:*

MedChem 600, *CNS Drugs section*, University of Michigan College of Pharmacy, Ann Arbor, MI, Fall 2014–2020

MedChem 660, *Research Ethics*, University of Michigan College of Pharmacy, Ann Arbor, MI, Fall and Winter, 2014–2021

Cellular Biotechnology 504, *Guest Lecturer*, University of Michigan, Ann Arbor, MI, Winter 2015

MedChem 532, *Nucleic Acid-Targeted Drugs section*, University of Michigan College of Pharmacy, Ann Arbor, MI, Fall 2016–2020, Fall 2022–2023  
Chem 548, *New Frontiers at the Chemistry Biology Interface*, University of Michigan, Ann Arbor, MI, Winter 2017  
Pharmacy 614, *Principles of Research and Problem Solving*, University of Michigan College of Pharmacy, Ann Arbor, MI, Winter 2018  
MedChem 410, *Concepts and Methods in Drug Discovery and Development*, University of Michigan College of Pharmacy, Ann Arbor, MI; course design and planning: Spring 2017–Summer 2018; teaching: Winter 2020–2023  
ChemBio 502, *Guest Lecturer*, University of Michigan, Ann Arbor, MI, Winter 2019–2022  
MedChem 610, *Endocrinology and Diabetes sections*, University of Michigan College of Pharmacy, Ann Arbor, MI, Winter 2023–present  
MedChem 532, *Course Designer, Coordinator, and Lecturer*, Chemical Biology in Drug Discovery, University of Michigan College of Pharmacy, Ann Arbor, MI, Winter 2024–present

*University of Pittsburgh:*

Chemistry 110, *Guest Lecturer*, University of Pittsburgh, Pittsburgh, PA, Spring 2008  
Chemistry 110, *Recitation and Laboratory Instructor*, University of Pittsburgh, Pittsburgh, PA, Spring 2008  
Chemistry 120, *Guest Lecturer*, University of Pittsburgh, Pittsburgh, PA, Spring 2005  
Tutor for Undergraduate and High School Chemistry Students, Pittsburgh, PA, 2004–2007  
Chemistry 120, *Recitation and Laboratory Instructor*, University of Pittsburgh, Pittsburgh, PA, Summer 2004 and Spring 2005  
Chemistry 120, *Recitation Instructor*, University of Pittsburgh, Pittsburgh, PA, Spring 2004  
Chemistry 110, *Recitation Instructor*, University of Pittsburgh, Pittsburgh, PA, Fall 2003

*Allegheny College:*

Peer-Led Team Leader for Organic Chemistry II, Allegheny College, Meadville, PA, Spring 2002 and 2003  
Peer-Led Team Leader for Organic Chemistry I, Allegheny College, Meadville, PA, Fall 2001 and 2002

**Mentoring Experience:**

*Postdoctoral Researchers:*

Dr. Lauren Mishra (September 2013–September 2014)  
Dr. Tanpreet Kaur (August 2016–April 2019)  
Dr. Emilio Cárdenas (August 2019–June 2024)  
Dr. Shruti Nagaraja (February 2021–July 2024)  
Dr. Maurinne Bonnet (May 2023–present)  
Dr. Eva Amatyia (January 2025–present)

*Graduate Students:*

Erin Gallagher (Medicinal Chemistry, 2014–2018)  
Oleta Johnson (Program in Chemical Biology, 2014–2018)  
Daniel Lorenz (Program in Chemical Biology, 2014–2018)  
James Song (Program in Chemical Biology, 2014–2018)  
Dylan Mitchell (Program in Chemical Biology, 2015–2019)  
Jorge Sandoval (Program in Chemical Biology, 2017–2018)  
Emily Sherman (Program in Chemical Biology, 2017–2019)  
Sydney Rosenblum (Program in Chemical Biology, 2018–2022)  
Rachel Torrez (Medicinal Chemistry, 2018–2022)  
Yihao Zhuang (Medicinal Chemistry, 2019–2023)  
José Reyes (Program in Chemical Biology, 2021–present)  
Dalia Soueid (Medicinal Chemistry, 2021–present)  
Rachel O'Rourke (Medicinal Chemistry, 2022–present)  
Gabriela Vega-Hernández (Program in Chemical Biology, 2022–present)  
Brandon Klein (Medicinal Chemistry, 2023–present)  
Marc Dean (Program in Chemical Biology, 2024–present)

*Rotation Students:*

Maureen Corriellus (Medicinal Chemistry, Winter 2014)  
April Tang (Chemistry, Winter 2014)  
Sumit Bandekar (Medicinal Chemistry, Fall 2014)  
Jason Miller (Medicinal Chemistry, Fall 2014)

Omari Baruti (Program in Chemical Biology, Winter 2015)  
Atsunori Kaneshige (Medicinal Chemistry, Fall 2016)  
Alex Ayoub (Program in Chemical Biology, Fall 2017)  
Yuning Shen (Medicinal Chemistry, Winter 2018)  
Glory Velazquez (Medicinal Chemistry, Winter 2018)  
Ryan Rutkoski (Medicinal Chemistry, Winter 2019)  
Jesse Wotring (Medicinal Chemistry, Winter 2019)  
Tommy Millunchick (Program in Chemical Biology, Fall 2020)  
Brad Clegg (Program in Chemical Biology, Fall 2020)  
Alex Kim (Program in Chemical Biology, Fall 2021)  
Robin Chen (Program in Chemical Biology, Fall 2021)  
Sahar Amin (Medicinal Chemistry, Winter 2022)  
Kathryn Hoegeman (Medicinal Chemistry, Winter 2022)  
Nikolaos Tripolitsiotis (Medicinal Chemistry, Fall 2023)  
Ileanxis Madera Cuevas (Medicinal Chemistry, Fall 2023)  
Sierra Hefferan (Medicinal Chemistry, Fall 2023)  
Yao Fu (Medicinal Chemistry, Fall 2023)  
Gina Kaup (Medicinal Chemistry, Winter 2024)  
Anupama Babulal (Program in Chemical Biology, Winter 2024)  
Jillian Murray (Medicinal Chemistry, Fall 2024)  
Rhiannon Stevens (Program in Chemical Biology, Fall 2024)  
Namrashee Mehta (Program in Chemical Biology, Fall 2024)  
Kate Desrochers (Program in Chemical Biology, Winter 2025)

*Research Staff:*

Arya Menon (October 2013–present)  
Samuel Kerk (February–June 2017)  
Andrea Maser (March 2022–March 2023)

*Master's Students:*

Evan Barnes (Summer 2017)  
Noha Beleh (January 2021–August 2021)

*PharmD Students:*

Thomas Hancock (October 2017–April 2018)  
Julianna Nichols (March 2024–present)

*Undergraduate Students:*

Hannah Foley (REU student from Central Michigan University, Summer 2015)  
Maxum Paul (REU student from Amherst College, Summer 2016)  
Alyah Chmiel (University of Michigan, Summer 2017–Summer 2018)  
Julia Crowther (University of Michigan, Fall 2019)  
Madeline Hinkley (University of Michigan, Fall 2019–Winter 2022)  
Casey McCarthy (University of Michigan, Summer 2022–Winter 2023)  
Evelyn Carroll (University of Michigan, Winter 2023–present)  
Charlotte Carozza (University of Michigan, Fall 2023–present)  
Nastasa Djordjevic (REU student from Illinois Institute of Technology, Summer 2024)  
Olivia Eby (University of Michigan, Fall 2024)

*Visiting Scholars:*

Prof. Leyte Winfield (Faculty Sabbatical, Spelman College, August 2017–July 2018)

*PREP Scholars:*

Gabriela Vega-Hernández (August 2020–July 2021)

*High School Students:*

Emma Blosser (June 2023–August 2023)



## **Mentee Awards:**

- Erin Gallagher: Pharmacological Sciences Training Program Trainee (2014–2016)  
Rackham Graduate Student Research Grant Awardee (2016)  
Kristen L. McGlone Research Award (2018)
- Oleta Johnson: Chemistry Biology Interface Training Program Trainee (2014–2016)  
Rackham Pre-Candidate Graduate Student Research Grant Awardee (2014)  
NSF Graduate Research Fellowship Awardee (2015–2018)  
Rackham Graduate Student Research Grant Awardee (2016)  
Carl Storm Underrepresented Minority Fellowship (2017)
- Daniel Lorenz: Rackham Pre-Candidate Graduate Student Research Grant Awardee (2014)  
Rackham Graduate Student Research Grant Awardee (2017)
- James Song: Cellular Biotechnology Training Program Trainee (2014–2016)  
Honorable Mention, NSF Graduate Research Fellowship (2015)  
Rackham Pre-Candidate Graduate Student Research Grant Awardee (2015)  
Rackham Graduate Student Research Grant Awardee (2017)
- Dylan Mitchell: Proteome Informatics of Cancer Training Program Trainee (2015–2017)  
Rackham Pre-Candidate Graduate Student Research Grant Awardee (2015)  
Rackham Graduate Student Research Grant Awardee (2017)  
Rackham Predoctoral Fellowship Awardee (2018)
- Jorge Sandoval: Chemistry Biology Interface Training Program Trainee (2017–2019)  
Rackham Pre-Candidate Graduate Student Research Grant Awardee (2018)
- Emily Sherman: NSF Graduate Research Fellowship Awardee (2017–2020)  
Rackham Pre-Candidate Graduate Student Research Grant Awardee (2017)
- Sydney Rosenblum: Rackham Pre-Candidate Graduate Student Research Grant Awardee (2018)  
RNA Society Travel Award (2020)  
ACS Division of Medicinal Chemistry Predoctoral Fellowship (2020–2021)
- Rachel Torrez: Pharmacological Sciences Training Program Trainee (2018–2020)  
NIH Ruth L. Kirschstein Predoctoral Individual National Research Service Award (2020–2022)
- Dr. Emilio Cárdenas: Scarborough Graduate/Postgraduate Award for Excellence in Medicinal Chemistry from the ACS Division of Medicinal Chemistry (2021)  
Merck Research Award for Underrepresented Chemists of Color (2021)  
UMPDA Conference Award (2021)
- José Reyes: NIH Supplement Fellowship (2021–2023)
- Dalia Soueid: Cellular Biotechnology Training Program Trainee (2021–2023)  
Rackham Pre-Candidate Graduate Student Research Grant Awardee (2022)  
ACS Division of Medicinal Chemistry Predoctoral Fellowship (2023–2024)  
Best Student Poster Award, Medicinal Chemistry Gordon Research Conference (2023)  
Department of Medicinal Chemistry Outstanding Graduate Student Research Award (2024)
- Yihao Zhuang: Department of Medicinal Chemistry Outstanding Graduate Student Research Award (2022)
- Dr. Shruti Nagaraja: UMPDA Professional Development Award (2022)
- Gabriela Vega-Hernández: NIH Supplement Fellowship (2022–2024)  
Rackham Pre-Candidate Graduate Student Research Grant Awardee (2023)
- Rachel O'Rourke: Department of Medicinal Chemistry Outstanding Graduate Student Instructor Award (2023)  
Best Poster Award, International Chemical Biology Society (ICBS) 2023 Meeting
- Dr. Maurinne Bonnet: Michigan Pioneer Post-doctoral Fellowship (2023)

## **Service:**

### *College of Pharmacy:*

Co-Chair, Graduate Admissions Committee, Medicinal Chemistry, Fall 2013–Winter 2014, Fall 2019

Pharmacy Family Mentor, Fall 2013–2017  
Faculty Advisor for COP Graduate Student Organization, Winter 2014–Spring 2016  
Chair, Graduate Admissions Committee, Medicinal Chemistry, Fall 2014–Winter 2019  
PharmD Admissions Committee Member, Fall 2014–Spring 2016  
Seminar Series Lead, Medicinal Chemistry, Summer 2015–Spring 2016, Summer 2019–Winter 2021  
Faculty Advisor for ACS Medicinal Chemistry Student Affiliate Chapter, Summer 2016–present  
Graduate Education Committee Member, Fall 2016–present  
Co-Chair, Faculty Search Committee, Medicinal Chemistry, Fall 2016–Winter 2017  
Team Science Committee Member, Summer 2017–2018  
Interdisciplinary REU Program Application Review Committee, Winter 2018  
First Year Advisor to the Medicinal Chemistry Graduate Students, Fall 2018–present  
Biosciences Initiative Faculty Search Committee Member, Winter 2019–Fall 2019  
Faculty Development Committee Member, Fall 2019–Winter 2021  
Rackham Faculty Ally, Fall 2020–Summer 2023  
Faculty Senate Representative, Fall 2020–Summer 2022  
Chair, Medicinal Chemistry Third Year Faculty Evaluation Committee, Summer 2021  
Pharmacy Dean Search Advisory Committee, Summer 2021–Winter 2022  
Director, Interdepartmental Program in Medicinal Chemistry, Winter 2022–present  
Chair, Faculty Search Committee, Medicinal Chemistry, Winter 2022–Fall 2022  
Executive Committee Member, Summer 2022–present  
Organizer, 1<sup>st</sup> Annual Medicinal Chemistry Retreat, Fall 2022  
Medicinal Chemistry Chair Search Advisory Committee, Winter 2023–Winter 2024  
College of Pharmacy Research Retreat Planning Committee, July 2024–October 2024

*University of Michigan:*

Admissions Committee Member for Program in Chemical Biology, 2013–2016

Thesis Committee Member:

John D. Nguyen, Stephenson Laboratory, Chemistry, Fall 2013–Summer 2014  
Jordan Walk, Montgomery Laboratory, Chemistry, Fall 2013–Winter 2014  
Sameer Phadke, Soellner Laboratory, Chemistry, Spring 2015  
Zachary Garlets, Wolfe Laboratory, Chemistry, Winter 2014–Winter 2017  
Cassie Joiner, Mapp Laboratory, Chemistry, Fall 2015–Winter 2017  
Michael Agius, Soellner Laboratory, Medicinal Chemistry, Fall 2014–Summer 2017  
Eric Lachacz, Soellner Laboratory, Medicinal Chemistry, Fall 2014–Summer 2017  
Yvonne DePorre, Schindler Laboratory, Chemistry, Fall 2014–Winter 2018  
Maxwell Stefan, Garcia Laboratory, Medicinal Chemistry, Fall 2014–Spring 2018  
Yangbing Li, Wang Laboratory, Medicinal Chemistry, Fall 2015–Spring 2018  
Anthony Nastase, Mosberg Laboratory, Medicinal Chemistry, Fall 2015–Summer 2018  
Emilia Groso, Schindler Laboratory, Chemistry, Fall 2014–Fall 2018  
Omari Baruti, Mapp Laboratory, Chemical Biology, Fall 2015–Spring 2019  
Martin Sevrin, Stephenson Laboratory, Chemistry, Spring 2016–Fall 2016  
Taylor Sodano, Stephenson Laboratory, Chemistry, Fall 2016  
Sumit Bandekar, Tesmer Laboratory, Medicinal Chemistry, Fall 2016–Fall 2019  
Shuai Hu, Neamati Laboratory, Medicinal Chemistry, Fall 2016–Summer 2020  
Amie Frank, Montgomery Laboratory, Chemistry, Fall 2016–Fall 2020  
Melody Sanders, Mapp and Ohi Laboratories, Chemical Biology, Fall 2016–Fall 2020  
Nicholas Foster, Mapp Laboratory, Chemical Biology, Fall 2016–Fall 2020  
Christine Cuthbertson, Neamati Laboratory, Medicinal Chemistry, Fall 2016–Fall 2020  
Nicholas Ragazzone, Garcia Laboratory, Medicinal Chemistry, Fall 2016–Fall 2022  
Jessica Yazarians, Narayan Laboratory, Chemistry, Fall 2017–Summer 2021  
Katherine Guild, Garcia Laboratory, Medicinal Chemistry, Fall 2017–Summer 2024

Monika Franco, Koutmos Laboratory, Chemical Biology, Summer 2018–Summer 2022  
Tyler Lefevre, Smrcka Laboratory, Chemical Biology, Summer 2018–Winter 2023  
Jorge Becerra, Mapp Laboratory, Chemical Biology, Fall 2018–Winter 2023  
Maha Hanafi, Neamati Laboratory, Medicinal Chemistry, Fall 2018–Winter 2020  
Miranda Simes, Cierpicki/Grembecka Laboratory, Chemical Biology, Summer 2019–Summer 2023  
Elizabeth Tidwell, Koutmos Laboratory, Biophysics, Fall 2019–Fall 2023  
Zachary Sluzala, Fort Laboratory, Neuroscience, Fall 2019–Fall 2024  
Garrett Dow, Garcia Laboratory, Medicinal Chemistry, Fall 2019–Fall 2022  
Glory Velazquez, Garcia Laboratory, Medicinal Chemistry, Fall 2019–present  
Charles Zhang, Sexton Laboratory, Medicinal Chemistry, Fall 2020–Summer 2023  
Troy Halseth, Schwendeman Laboratory, Medicinal Chemistry, Fall 2020– Summer 2023  
Wenbin Tu, Wang Laboratory, Medicinal Chemistry, Fall 2020–Fall 2023  
Sicong Ma, Keane Laboratory, Biophysics, Fall 2020–Winter 2024  
Shannon Miller, Todd Laboratory, Cell and Molecular Biology, Fall 2021–present  
Tommy Millunchick, Keane Laboratory, Chemical Biology, Fall 2021–Summer 2023  
Alex Kim, Narayan Laboratory, Chemical Biology, Fall 2022–present  
Mya Gough, Toogood Laboratory, Medicinal Chemistry, Fall 2022–present  
Mason Baber, Toogood Laboratory, Medicinal Chemistry, Fall 2022–present  
Arya Menon, Moon Laboratory, Chemical Biology, Fall 2023–present  
Grace McIntyre, DiFeo Laboratory, Pathology, Fall 2023–present  
Anupama Babulal, Nandakumar Laboratory, Chemical Biology, Fall 2024–present  
Geoff Hewett, Cierpicki/Grembecka Laboratory, Chemical Biology, Fall 2024–present  
Youngseo Na, Schwendeman Laboratory, Medicinal Chemistry, Fall 2024–present  
Manasa Yadavalli, O’Meara Laboratory, Computational Medicine/Bioinformatics, Fall 2024–present  
Chemistry Biology Interface Training Program, Selection Committee, 2015–2019  
Michigan Life Sciences Fellows Review Committee, Fall 2017–2019  
Center for Chemical Genomics Oversight Committee, 2018–2020  
Scientific Advisory Committee Member, Structure and Drug Screening Shared Resource, Rogel Cancer Center, 2018–present  
Rogel Cancer Center Research Committee, 2021–present  
Cellular Biotechnology Training Program, Faculty Executive Committee, 2021–present  
Forbes Institute Review Committee, 2022  
Faculty Advisor for University of Michigan Young Science Innovators (U-MYScI), Fall 2023–present  
Program in Chemical Biology, Admissions Committee Member, Fall 2023–Winter 2024

*National/International:*

Peer Reviewer for the following journals:

ACS Central Science  
ACS Chemical Biology  
ACS Combinatorial Science  
ACS Infectious Diseases  
ACS Medicinal Chemistry Letters  
ACS Pharmacology and Translational Science  
BBA – General Subjects  
Biochemistry  
Bioconjugate Chemistry  
Bioorganic and Medicinal Chemistry  
Bioorganic and Medicinal Chemistry Letters  
Biopolymers  
Bio-protocol  
British Journal of Pharmacology  
Cell Chemical Biology

ChemBioChem  
Chemical Communications  
Chemical Science  
Chemistry – A European Journal  
Current Opinion in Chemical Biology  
European Journal of Medicinal Chemistry  
Experimental Cell Research  
Journal of the American Chemical Society  
Journal of Medicinal Chemistry  
Marine Drugs  
Methods in Enzymology  
Nature Chemical Biology  
Nature Communications  
Nature Protocols  
Nature Reviews Drug Discovery  
Nucleic Acids Research  
Organic and Biomolecular Chemistry  
Organic Letters  
PLoS ONE  
Proceedings of the National Academy of Sciences of the United States of America  
RSC Advances  
RSC Medicinal Chemistry  
Science Advances  
Scientific Reports  
SLAS Discovery  
Tetrahedron

NIH Grant Review:

ZRG1 OTC-N 80 A, AREA: Oncological Sciences Grant Applications, ad hoc, 2015  
Drug Discovery and Molecular Pharmacology (DMP) Study Section, ad hoc, 2016, 2018 (×2), 2019  
Small Business: Drug Discovery and Development BCMB (10) Study Section, ad hoc, 2016, 2019  
High-Throughput Screening Study Section BST-55, ad hoc, 2017 (×3)  
Synthetic and Biological Chemistry B (SBCB) Study Section, ad hoc, 2018, 2020  
DMP Study Section, standing member, July 2020–June 2024  
NCI Innovative Molecular and Cellular Analysis Technologies (IMAT) Special Emphasis Panel, 2022  
NCI Chemical Biology Laboratory Site Visit, 2022  
NSF CAREER, ad hoc, 2023  
NIH Director’s Early Independence Award Reviewer, ad hoc, 2024

International Grant Review:

Singapore Ministry of Education’s Academic Research Fund (AcRF) Tier 2, 2015–2021  
Genome Canada, 2020

Consulting Work:

Vida Ventures  
Third Rock Ventures  
GreatPoint Ventures  
Arrakis Therapeutics  
Flagship Pioneering  
Ladder Therapeutics  
aMoon Fund  
5AM Ventures  
D. E. Shaw Research  
Novo Holdings

Skyhawk Therapeutics, Scientific Advisory Board member  
Janssen Oncology  
The Column Group  
Ribometrix  
Maze Therapeutics  
Biogen, Scientific Advisory Board, November 2022  
Atomic AI, Scientific Advisory Board member

Conferences and Symposia:

Discussion Leader, Gordon Research Conference (Bioorganic Chemistry), Andover, NH, 2018  
Poster Judge, Gordon Research Conference (Bioorganic Chemistry), Andover, NH, 2018  
Poster Judge, Gordon Research Conference (Medicinal Chemistry), New London, NH, 2018  
Co-Organizer, “Reinventing Drug Discovery through Chemical Biology” Symposium sponsored by Cayman Chemical, Ann Arbor, MI, 2019  
Chair, “Chemical Biology and Target Validation” Symposium, World Pharma Week, Boston, MA, 2019  
Session Organizer and Chair, 258<sup>th</sup> ACS National Meeting, “MEDI: Rising Stars: Women in Medicinal Chemistry,” San Diego, CA, 2019  
Session Organizer and Co-Chair, 262<sup>nd</sup> ACS National Meeting, “Cryo-EM in Drug Discovery,” Atlanta, GA, 2021  
Round Table Moderator, Women in Targeting the Undrugged Congress, Targeting RNA group, 2021  
Session Organizer and Chair, 263<sup>rd</sup> ACS National Meeting, “The Long Trip: A Resurgence of Psychedelic Drugs,” San Diego, CA, 2022  
Session Organizer and Co-Chair, 264<sup>th</sup> ACS National Meeting, “Molecular Glues,” Chicago, IL, 2022  
Round Table Participant, “Implementing a Diverse, Equitable, and Inclusive Culture in Medicinal Chemistry,” 264<sup>th</sup> ACS National Meeting, Chicago, IL, 2022  
Session Organizer and Co-Chair, 265<sup>th</sup> ACS National Meeting, “Lost in Translation? Targeting Protein Synthesis as a Therapeutic Strategy,” Indianapolis, IN, 2023  
Session Organizer and Chair, 266<sup>th</sup> ACS National Meeting, “Drugging pre-mRNA Splicing,” San Francisco, CA, 2023  
Session Organizer and Co-Chair, 266<sup>th</sup> ACS National Meeting, “New Approaches in Antibiotic Discovery,” San Francisco, CA, 2023  
Session Organizer and Chair, International Chemical Biology Society (ICBS) 2023 Meeting, “RNA Biology,” Ann Arbor, MI, 2023  
Session Organizer and Co-Chair, 267<sup>th</sup> ACS National Meeting, “Chemoproteomic Approaches in Drug Discovery,” New Orleans, LA, 2024  
Session Organizer and Co-Chair, 268<sup>th</sup> ACS National Meeting, “Modern Phenotypic Screening,” Denver, CO, 2024  
Session Organizer and Co-Chair, 268<sup>th</sup> ACS National Meeting, “The Future of RNA-Targeted Drug Discovery,” Denver, CO, 2024  
Session Organizer and Chair, XXVIII EFMC International Symposium on Medicinal Chemistry, “DNA-Encoded Libraries,” Rome, Italy, 2024  
Session Co-Chair, XXVIII EFMC International Symposium on Medicinal Chemistry, “Early Career Women in Medicinal Chemistry and Chemical Biology,” Rome, Italy, 2024

National Societies:

ACS Division of Medicinal Chemistry, Long-Range Planning Committee, 2020–2023  
ACS Division of Medicinal Chemistry, Award Committee, 2023–2024  
ACS Division of Medicinal Chemistry, Officer Nominating Committee, 2024–present

**Professional Societies:**

American Chemical Society, 2002–present  
IS3NA, 2018–present  
American Society for Biochemistry and Molecular Biology, 2019–present

American Association for Cancer Research, 2024–present